# China NMPA Drug Inspection - Anguo Lulutong Traditional Chinese Medicine Pieces Co., Ltd. - Amomum villosum

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anguo-lulutong-traditional-chinese-medicine-pieces-co-ltd/0e740933-14d9-4c3c-b622-3d9060df50fb/
Source feed: China

> China NMPA drug inspection for Anguo Lulutong Traditional Chinese Medicine Pieces Co., Ltd. published December 29, 2017. Drug: Amomum villosum. On December 29, 2017, the State Administration for Market Regulation (NMPA) announced findings from inspections revealin

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 228 of 2017 from the State Administration of Traditional Chinese Medicine regarding 38 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Anguo Lulutong Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2017-12-29
- Drug Name: Amomum villosum
- Inspection Finding: The non-compliant items included appearance and content determination.
- Action Taken: Relevant provincial-level food and drug administration departments have taken control measures such as sealing and seizing goods, requiring enterprises to suspend sales and use, recall products, and rectify the situation. The State Food and Drug Administration has instructed the provincial-level food and drug administration departments where the relevant units are located to investigate the illegal acts of producing and selling substandard drugs by the aforementioned enterprises in accordance with Articles 73, 74, and 75 of the "Drug Administration Law of the People's Republic of China," and to publicly disclose the results of the investigation and report the relevant situation within three months.
- Summary: On December 29, 2017, the State Administration for Market Regulation (NMPA) announced findings from inspections revealing 38 batches of unqualified Traditional Chinese Medicine (TCM) decoction pieces from 29 enterprises. Inspections, led by institutions including the China National Institutes for Food and Drug Control, identified various quality issues. Violations included substandard appearance and identification for 13 batches of Bletilla striata, produced by companies such as Beijing Bencao Fangyuan Pharmaceutical Co., Ltd. Additionally, 23 batches of Amomum villosum, from companies including Anhui Yiyuantang Traditional Chinese Medicine Pieces Technology Co., Ltd., displayed substandard appearance and content determination. Other products like Codonopsis pilosula and Eupolyphaga sinensis also showed appearance deficiencies. In response, provincial food and drug administrations implemented control measures, seizing and sealing substandard products. Affected companies were ordered to suspend sales, recall products, and undertake rectifications. The NMPA directed provincial authorities to investigate these breaches under Articles 73, 74, and 75 of the "Drug Administration Law of the People's Republic of China." Public disclosure of investigation outcomes for the involved entities was mandated within three months, with provisions for severe penalties against manufacturers if product authenticity objections are disproven. This action underscores the NMPA's commitment to upholding drug quality and ensuring public health.

Company: https://www.globalkeysolutions.net/companies/anguo-lulutong-traditional-chinese-medicine-pieces-co-ltd/14e9df8b-b3b0-44dd-ae39-a5c87a2dc03e/